Published in Medical Letter on the CDC and FDA, November 30th, 2003
Tricor (fenofibrate capsules) micronized was formerly marketed by Abbott Laboratories, Inc., (ABT) for the treatment of very high serum triglyceride levels.
Abbott has previously discontinued sales of the capsule form and has replaced it in the market with a tablet formulation.
IMPAX currently has 17 applications pending at the FDA, including 3 tentatively approved, which address approximately $7 billion in U.S....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.